Article | June 14, 2022

Outsourcing Differences By Company Size — Biologic Drug Substance Manufacturing

Source: ISR Reports

By Kate Hammeke, VP of Market Research, Industry Standard Research (ISR) @ISRreports

Kate 2021_450x300

The maturation of the outsourcing industry comes with various benefits, a notable one being the removal of the multimillion- dollar financial barrier of in-house manufacturing for new and emerging companies. Virtual biopharmas are able to use CDMOs to further their discoveries through access to state-of-the-art manufacturing facilities, regulatory knowledge, and scientific expertise not possessed in-house. The proliferation of startup biopharmas over the past couple of decades will certainly speed up the pace of new medicines coming to market and hopefully improve and extend the lives of patients in the process.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online